This company listing is no longer active
Oncodesign Société Anonyme Future Growth
Future criteria checks 5/6
Key information
101.2%
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 5.0% |
Revenue growth rate | 14.7% |
Future return on equity | 46.3% |
Analyst coverage | Low |
Last updated | n/a |
Recent future growth updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | 54 | 10 | 8 | N/A | 1 |
12/31/2023 | 55 | 8 | 1 | N/A | 2 |
12/31/2022 | 49 | -2 | -1 | N/A | 2 |
6/30/2022 | 33 | -6 | N/A | N/A | N/A |
3/31/2022 | 32 | -3 | N/A | N/A | N/A |
12/31/2021 | 32 | 0 | -2 | 1 | N/A |
9/30/2021 | 33 | 1 | N/A | N/A | N/A |
6/30/2021 | 38 | 2 | -8 | -5 | N/A |
3/31/2021 | 38 | 2 | -1 | 1 | N/A |
12/31/2020 | 34 | 2 | 6 | 8 | N/A |
9/30/2020 | 36 | 2 | N/A | N/A | N/A |
6/30/2020 | 38 | 1 | 6 | 8 | N/A |
3/31/2020 | 38 | 1 | 2 | 4 | N/A |
12/31/2019 | 39 | 2 | -2 | 0 | N/A |
9/30/2019 | 36 | 1 | N/A | N/A | N/A |
6/30/2019 | 34 | 1 | 2 | 6 | N/A |
3/31/2019 | 31 | -1 | 0 | 3 | N/A |
12/31/2018 | 28 | -3 | -3 | 0 | N/A |
9/30/2018 | 25 | -5 | N/A | N/A | N/A |
6/30/2018 | 24 | -7 | -13 | -8 | N/A |
3/31/2018 | 23 | -6 | -11 | -7 | N/A |
12/31/2017 | 22 | -5 | -10 | -6 | N/A |
9/30/2017 | 23 | -2 | -4 | -2 | N/A |
6/30/2017 | 18 | 1 | 1 | 3 | N/A |
3/31/2017 | 15 | 1 | 1 | 2 | N/A |
12/31/2016 | 15 | 1 | 0 | 1 | N/A |
9/30/2016 | 14 | 0 | N/A | N/A | N/A |
6/30/2016 | 14 | 0 | -2 | -1 | N/A |
3/31/2016 | 15 | 1 | N/A | -1 | N/A |
12/31/2015 | 15 | 1 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALONC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).
Earnings vs Market: ALONC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ALONC is expected to become profitable in the next 3 years.
Revenue vs Market: ALONC's revenue (14.7% per year) is forecast to grow faster than the French market (5.1% per year).
High Growth Revenue: ALONC's revenue (14.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALONC's Return on Equity is forecast to be very high in 3 years time (46.3%).